Funder
Japan Society for the Promotion of Science
Reference45 articles.
1. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine;Groenland;Eur. J. Clin. Pharmacol.,2019
2. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma;Shiraishi;Nat. Commun.,2016
3. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014
4. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives;Zhong;Signal Transduct. Targeted Ther.,2021
5. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer;Spigel;J. Clin. Oncol.,2011
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献